Ten post jest także dostępny w języku: polski
Only until the end of March Jarek Oleszczuk was the President of the Management Board of AstraZeneca Pharma Poland. The information about the end of cooperation was confirmed by both the company and Oleszczuk on his profile on LinkedIn.
Oleszczuk has doubled the AstraZeneca business
Jarek Oleszczuk worked in AstraZeneca for the last four years. During this time, employment in the company’s Polish branch has increased from 500 to 1,800 people. The company also introduced a record number of drugs in the field of oncology, asthma and diabetes, doubling its business.
Previously, Oleszczuk was associated with, among others, Novartis, where he was Head of Commercial Operations and Head of Innovative Medicines Division in Poland, as well as head of the company’s branch in the Baltic States. He was also CEO of Abbott Poland and CEO of AbbVie first in Poland and later in Belgium and Luxembourg.
At the same time, at the end of March, Oleszczuk ceased to serve on the Supervisory Board of Infarma.
Focus on life science
Now Oleszczuk intends to get involved in life science. He is a co-founder of the biotechnology company Axcend Health, which aims to support new discoveries in biotechnology and medical technologies. It is to ensure this by, among others, providing scientists and inventors with funding and strategic support at the initial stage of development, providing access to laboratory space or support in establishing cooperation with universities and research institutions.
He is also a member of the Scientific Council of Orphinic Scientific, whose activities focus on orphan drugs (late preclinical phase and phases I and II of clinical trials).
Photo: Jarek Oleszczuk Twitter.